Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA, USP Collaborate To Promote Generic Development In Reversal Of Biosimilar Clash

Executive Summary

Talks remain in early stages, but both sides thinking 'outside the box' to come up with potential policy updates to generate more generic competition and bring down drug prices.

You may also be interested in...



How Drug Promotion Might Change Under Trump's Rx Pricing Plan

DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.

Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?

US FDA softens its tone on idea and encourages industry to voice its (predominantly negative) opinion publicly.

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

To remain shielded from political forces that could change incentives, pharmaceutical industry must adopt 'a certain set of values,' US FDA Commissioner says.

Related Content

Topics

UsernamePublicRestriction

Register

GB002345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel